Trial Profile
A Phase II, Multicenter, Single-arm Study of Oral LDK378 in Crizotinib naive Adult Patients With ALK-activated Non-small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ceritinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ASCEND III
- Sponsors Novartis Pharmaceuticals
- 25 Nov 2019 Final results published in the Journal of Thoracic Oncology.
- 19 Jul 2018 Status changed from active, no longer recruiting to completed.
- 07 Mar 2018 This trial has been completed in Belgium (end date: 2018-01-22)